Durect Seeking to Initiate Larsucosterol Phase 3 Trial in 2024 With Topline Results Expected in 2H 2026 >DRRX
Durect Seeking to Initiate Larsucosterol Phase 3 Trial in 2024 With Topline Results Expected in 2H 2026 >DRRX
durect寻求于2024年开始进行拉苏可斯特罗第三期试验,预计于2026年下半年发布头条结果>>DRRX
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册